362519-49-1

Basic information

• Product Name: SLV-319
• Synonyms: rac-(±)-SLV 319;(±)-SLV319(Ibipinabant)
• CAS NO: 362519-49-1
• Molecular Formula: C₂₃H₂₀Cl₂N₄O₂S
• Molecular Weight: 487.409
• Mol File: 362519-49-1.mol

Chemical Properties

• Boiling Point: 623.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.38±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Soluble in DMSO
• PKA: 11?+-.0.60(Predicted)
• CAS DataBase Reference: SLV-319(CAS DataBase Reference)
• NIST Chemistry Reference: SLV-319(362519-49-1)
• EPA Substance Registry System: SLV-319(362519-49-1)

Safety Data

• Hazardous Substances Data: 362519-49-1(Hazardous Substances Data)

Usage

Uses

(+/-)-SLV 319 is a mixture of the CB1 antagonist SLV 319 and its distomer.

Biological Activity

slv 319 is described here instead of (±)-slv 319. slv 319, also called ibipinabant, is a cb1 antagonist with an ic50 value of 22 nm [1, 2].there are 2 types of cannabinoid receptors (cb1 and cb2). their endogenous ligands are primarily anandamide and 2-ag. cannabinoid receptors and their endogenous ligands together are prominent in the control of food intake and energy metabolism. stimulation of this endocannabinoid system triggers metabolic processes and leads to lipogenesis, weight gain, insulin resistance, dyslipidemias and impaired glucose homeostasis [2].c2c12 murine myoblasts were model cells. exposure to increasing concentrations of ibipinabant at the highest concentration tested (100 μm) for 24 hours significantly decreased cell viability to 73 ± 5%. after 48 hours of exposure to the drug at this concentration only 33 ± 4% of cells remained viable. cellular reactive oxygen species (ros) generation is an index of mitochondrial function. a more than 2-fold increase in cellular ros generation could already be observed after 8 hours exposure to ibipinabant at a concentration of 100 μm compared to the vehicle treated c2c12 myoblasts [3].cb1 receptor occupancy was related to potencies to increase dopamine (da) and norepinephrine (ne) releases. in the medial prefrontal cortex (mpfc), slv 319 caused a significant increase in the extracellular da level at 10 mg/kg. the time course of the effects of slv 319 and sr141716a at the 10-mg/kg dose appeared to be similar with peak effects at 30 and 180 min. but slv 319 showed a more pronounced biphasic effect on da release. slv319 administration caused significant increases in extracellular concentrations of 3,4-dihydroxyphenylacetic acid (dopac) and homovanillic acid (hva), metabolites of da and ne, after the 10-mg/kg dose in rat [4].

references

[1]. srivastava bk, soni r, joharapurkar a, et al. bioisosteric replacement of dihydropyrazole of 4s-(-)-3-(4-chlorophenyl)-n-methyl-n’-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1h-pyrazole-1-caboxamidine (slv-319) a potent cb1 receptor antagonist by imidazole and oxazole. bioorganic & medicinal chemistry letters, 2008, 18(3): 963-968.[2]. chorvat rj, berbaum j, seriacki k, et al. jd-5006 and jd-5037: peripherally restricted (pr) cannabinoid-1 receptor blockers related to slv-319 (ibipinabant) as metabolic disorder therapeutics devoid of cns liabilities. bioorganic & medicinal chemistry letters, 2012, 22(19): 6173-6180.[3]. schirris tjj, ritschel t, renkema gh, et al. mitochondrial adp/atp exchange inhibition: a novel off-target mechanism underlying ibipinabant-induced myotoxicity. scientific reports, 2015, 5.[4]. need ab, davis rj, alexander-chacko jt, et al. the relationship of in vivo central cb1 receptor occupancy to changes in cortical monoamine release and feeding elicited by cb1 receptor antagonists in rats. psychopharmacology, 2006, 184(1): 26-35.

Upstream product

• 59074-26-9 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 
• 1207386-64-8 3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide 
• 98-64-6 4-Chlorobenzenesulfonamide 
• 1207386-65-9 methyl 3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioimidate 
• 464213-17-0 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide 
• 34543-04-9 N-[(4-chlorophenyl)sulfonyl]carbamic acid methyl ester 
• 74-89-5 methylamine 
• 362519-51-5 4-Chloro-N-[1-chloro-1-[3-(4-chloro-phenyl)-4-phenyl-4,5-dihydro-pyrazol-1-yl]-meth-(E)-ylidene]-benzenesulfonamide 

Relevant articles and documents

An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant

A novel synthetic route to the highly selective and orally active cannabinoid CB1 receptor inverse agonist ibipinabant is described which combines the use of inexpensive, commercially available reagents and mild reaction conditions with a high

SYNTHESIS OF 3,4-DIARYL-4,5-DIHYDRO-(1H)-PYRAZOLE-1- CARBOXAMIDINE DERIVATIVES

The invention relates to a novel chemical route to 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamidine derivatives, known as potent cannabinoid-CB1 receptor antagonists, and to novel intermediates of these compounds. The synthetic route produced considerably higher yields than those reported, without the use of corrosive reagents. The process concerns the preparation of a compound of formula (I) wherein the symbols have the meanings given in the description.

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists

A series of novel 3,4-diarylpyrazolines was synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays. The 3,4-diarylpyrazolines elicited potent in vitro CB1 antagonistic activities and in general exhibited high CB1 vs CB2 receptor subtype selectivities. Some key representatives showed potent pharmacological in vivo activities after oral dosing in both a CB agonist-induced blood pressure model and a CB agonist-induced hypothermia model. Chiral separation of racemic 67, followed by crystallization and an X-ray diffraction study, elucidated the absolute configuration of the eutomer 80 (SLV319) at its C4 position as 4S. Bioanalytical studies revealed a high CNS-plasma ratio for the development candidate 80. Molecular modeling studies showed a relatively close three-dimensional structural overlap between 80 and the known CB1 receptor antagonist rimonabant (SR141716A). Further analysis of the X-ray diffraction data of 80 revealed the presence of an intramolecular hydrogen bond that was confirmed by computational methods. Computational models and X-ray diffraction data indicated a different intramolecular hydrogen bonding pattern in the in vivo inactive compound 6. In addition, X-ray diffraction studies of 6 revealed a tighter intermolecular packing than 80, which also may contribute to its poorer absorption in vivo. Replacement of the amidine -NH2 moiety with a -NHCH3 group proved to be the key change for gaining oral biovailability in this series of compounds leading to the identification of 80.